Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-[3H]-2,4-dioxo-3,4-dihydrothieno.3,2-d] pyrimidin1(2H)- yl) propanoic acid ([3H]-NF608)

Alcaide, Anna; Marconi, Laura; Marek, Ales; Haym, Isabell; Nielsen, Birgitte; Møllerud, Stine; Jensen, Mikael; Conti, Paola; Pickering, Darryl S.; Bunch, Lennart

Published in:
MedChemComm

Link to article, DOI:
10.1039/c6md00339g

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Alcaide, A., Marconi, L., Marek, A., Haym, I., Nielsen, B., Møllerud, S., ... Bunch, L. (2016). Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-[3H]-2,4-dioxo-3,4-dihydrothieno.3,2-d] pyrimidin1(2H)- yl) propanoic acid ([3H]-NF608). MedChemComm, 7(11), 2136-2144. DOI: 10.1039/c6md00339g
Synthesis and pharmacological characterization of the selective GluK1 radioligand (S)-2-amino-3-(6-[³H]-2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)propanoic acid ([³H]-NF608)†‡

Anna Alcaide, Laura Marconi, Ales Marek, Isabell Haym, Birgitte Nielsen, Stine Møllerud, Mikael Jensen, Paola Conti, Darryl S. Pickering and Lennart Bunch

The kainic acid receptors belong to the class of ionotropic glutamate receptors and comprise five subunits named GluK1–5. Radioligands are essential tools for use in binding assays aimed at ligand–receptor structure–activity–relationship studies. Previous work has led to the synthesis of GluK1 radioligands [³H]-SYM2081, [³H]-UBP310 and [³H]-ATPA, however all strategies were work-intensive and thus not attractive. Herein, we report the synthesis of [³H]-NF608 and subsequent pharmacological evaluation at homomeric recombinant rat GluK1 receptors. Binding affinities of a series of standard GluK1 ligands were shown to be in line with previously reported affinities obtained by use of already reported radioligands.

Introduction

The kainic acid (KA, Fig. 1A) receptors belong to the class of ionotropic glutamate receptors and are believed to mediate a modulatory excitatory response in the central nervous system. The KA receptors comprise five subunits, termed GluK1–5 and are tetrameric in structure (dimer of dimers). While the subunits GluK1–3 may form functional homomeric as well as heteromeric receptors, subunits GluK4,5 only form functional receptors with GluK1–3. To study the role and function of each of the KA receptor subtypes, it is essential that subtype selective ligands (pharmacological tools) are available. While selective GluK1 agonists and antagonists have been reported (Fig. 1B), selective ligands for the GluK2–5 subtypes remain to be discovered. In order to achieve this, extensive structure–activity–studies are continuously performed, which includes binding affinity studies of synthesized compounds at homomeric, recombinant KA receptor subtypes. Readily accessible radioligands are essential to accomplish this, and previous work-intensive strategies have led to the synthesis of [³H]-UBP310 and [³H]-ATPA (ref. 4) (Fig. 1C) as GluK1-selective radioligands. The high affinity KA receptor ligand SYM2081 (Fig. 1C) has also been employed as the radioligand in binding assays of homomeric GluK1–3 receptors, however its difficult purification makes it less attractive to produce and it is no longer commercially available. While commercially available [³H]-KA can be successfully used in radioligand binding studies for GluK2 (kd = 6.5 nM) (Fig. 2), GluK3 (kd = 8.0 nM) (Fig. 2), GluK4 LBD (kd = 1.9 nM) (Kristensen et al., 2016) and GluK5 (kd = 6.9 nM) (Møllerud et al., 2016) it has 10-fold lower affinity at GluK1 (kd = 67 nM) (Fig. 2) making it a less than ideal radiolabel for binding studies at GluK1. Here we report the synthesis and pharmacological characterization of [³H]-NF608 – a new high affinity, GluK1-selective radioligand.

Results and discussion

Synthesis

Firstly, we pursued a direct bromination of commercially available UBP310 to obtain the dibromothiophene precursor previously reported for the synthesis of [³H]-UBP310 (Scheme S1, ESI†). However, bromination took place at the uracil ring only, and all attempts failed to following incorporate deuterium (see ESI† for details).

We next turned to investigate the high affinity, selective GluK1 ligand NF608 (Fig. 1) which also comprises a thioephene ring. Its synthesis is described in only two steps from commercially available thieno[3,2-d]pyrimidine-2,4(1H,3H)-
dione (1) (Scheme 1). Firstly, we attempted bromination of the thiophene ring of 3 under standard conditions (Br₂ in AcOH or TFA, rt to 90 °C) (Scheme 1). However, none of the corresponding bromo or dibromo derivatives comprised by general structure 4 were observed but only the expected cleavage of the BOC group.

We therefore revised the strategy to introduce the bromine functionality earlier in the synthesis (Scheme 1), and indeed we were able to brominate the thiophene ring of 1 in the 7 position to give 5. Disappointingly, alkylation at N¹ with lactone 2 (ref. 12) as the electrophile was unproductive (NaH, DMF, −65 to 80 °C) presumably due to the bulkiness of the bromine atom (Scheme 1). For that reason, we turned to pursue bromination of the 6 position of the thienopyrimidine ring in order to allow for following alkylation at N³.

The synthesis of key bromo intermediate 13 (Scheme 2) commenced with N-protection of commercially available methyl 3-aminothiophene-2-carboxylate (7) with trichloroacetyl isocyanate in THF to afford compound 8 in 93% yields. Subsequent bromination with Br₂ in acetic acid at 80 °C successfully provided exclusively 5-bromo-thiophene 9, which was then treated with 2 M ammonia in methanol to afford urea 10. Cyclization with potassium tert-butoxide in DMF, furnished the desired heterocyclic product 11. Alkylation at N¹ with lactone 2 was performed using sodium hydride as base in DMF, as described in a similar procedure. The alkylation product 12 was obtained in only 18% yield which could likely be optimized. Cleavage of the BOC group in the presence of 2 M aq HCl provided key bromo amino acid intermediate 13, in overall 6 steps. Deuteration over Pd/C in a basic aqueous media gave 80% deuterium incorporation, furnishing deuterated product [D₆]-NF608 together with NF608, in overall 57% yield.

Tritiation

Having established the method for deuterium incorporation, tritiation was carried out by use of T₂ (gas) with Pd/C as catal-

lyst in water to give [³H]-NF608 in high yield (Scheme 3) at a specific activity of 16.3 Ci mmol⁻¹.

Radiochemical stability

Formulation of [³H]-NF608 was chosen as a 1 mCi mL⁻¹ solution in H₂O–EtOH (1:1) and the radiochemical stability was monitored over time. When stored at −21 °C, the stability was determined to be 98% after 42 days and 97.5% after 90 days. When stored at −196 °C for 90 days, no decomposition could be detected.

GluK1 binding pharmacology

Assay validation

Based upon our previous publication we anticipated [³H]-NF608 to be a high affinity radioligand at GluK1 since unlabeled NF608 had shown a Kᵢ of 5.3 nM. Initial tests indicated high level of specific binding of the radiolabel to homomeric rat GluK1 expressed in sf9 cell membranes and subsequently an assay validation was conducted using 1 mM (S)-glutamate to define nonspecific binding. No specific binding was seen using uninfected sf9 cell membranes. A series of buffers, temperatures, pH conditions and washing protocols were evaluated (Table 1) and 50 mM Tris-HCl pH 7.1 at 4 °C with 2 × 4 mL filter washes was found to be optimal for specific binding to GluK1. There was no pH dependency of the binding between pH 7.1 and 7.8. Binding of [³H]-NF608 to native GluK1 in rat brain P2 membranes was tested using the high affinity GluK1-selective ligand 10 µM UB310 to evaluate nonspecific binding and, although a small amount of specific binding was detected, it was insufficient to perform pharmacological analyses at native GluK1. This is likely due to the low specific activity of the radioligand (16.3 Ci mmol⁻¹).

Kinetics

The association and dissociation kinetics of [³H]-NF608 binding were examined at GluK1 at 4 °C (Fig. 3). The association
rate was measured as $(\text{mean } \pm \text{SEM}) k_{\text{on}} = 10.05 \pm 1.30 \times 10^6 \text{ min}^{-1} \text{ nM}^{-1} (n = 3)$ and the dissociation rate determined as $(\text{mean } \pm \text{SEM}) k_{\text{off}} = 0.0274 \pm 0.0017 \text{ min}^{-1} (n = 4)$. The time course of binding at $4 \text{ °C}$ indicated that equilibrium is attained by 1 h. Calculation of the affinity from the kinetic rate constants gave a kinetic $K_d$ (mean ± SEM) = 2.72 ± 0.39 nM, which agrees well with the previously determined affinity of NF608 at GluK1 $(K_i = 5.29 \pm 0.66 \text{ nM})$.7

**Saturation**

The equilibrium binding affinity of $[^{3}H]$NF608 at GluK1 was measured in saturation binding (Fig. 4) where (mean ± SEM, $n = 3$) $K_d = 6.68 \pm 0.88 \text{ nM}, B_{\text{max}} = 5829 \pm 248 \text{ fmol mg}^{-1} \text{ protein}$. This affinity is not statistically significantly different ($p = 0.251$, t-test) from our previously determined affinity of NF608 at GluK1 using $[^{3}H]$SYM2081 as the radioligand.

**Competition**

The pharmacological profile of a selected series of KA receptor ligands was examined using $[^{3}H]$NF608 (Fig. 5). A comparison of the profile to that previously observed using $[^{3}H]$SYM2081 as the radioligand7 shows reasonable agreement and Hill values are near unity for all ligands tested (Table 2). Analysis of homologous competition binding with NF608 yielded a $K_d = 6.93 \text{ nM} (pK_d = 8.160 \pm 0.047)$ (Fig. 6), which is identical to the $K_d$ determined from saturation analysis.

**Conclusion**

In conclusion we have reported a short and efficient method for the radiosynthesis of the selective GluK1 radioligand $[^{3}H]$-NF608. The radioligand was characterized in *in vitro* binding assays at cloned homomeric GluK1 receptors and binding affinities ($K_i$) of a series of standard GluK1 ligands were shown to be in line with previously reported affinities obtained by use of already reported radioligands.

**Experimental section**

**Chemistry**

All reactions involving dry solvents or sensitive agents were performed under a nitrogen or argon atmosphere, and glassware was dried prior to use. Commercially available chemicals were used without further purification. Solvents were dried prior to use with an SG water solvent purification system or dried by standard methods. Reactions were monitored by analytical thin-layer chromatography (TLC, Merck silica gel 60 F254 aluminum sheets), analytical HPLC or UPLC. Flash chromatography was carried out using the Merck silica gel 60 (15–40 μm) or Merck silica gel 60 (40–63 μm). $^1H$ NMR spectra were recorded on a 400 MHz Bruker Avance III or 600 MHz Bruker Avance III HD, and $^{13}C$ NMR spectra on a 101 MHz Bruker Avance III or 151 MHz Bruker Avance III HD. Chemical shifts are reported in δ (ppm) relative to the singlet at δ = 7.26 ppm of CDCl3, the quintet at 2.50 ppm of DMSO-d6 for $^1H$ NMR, and to the centre line of the triplet at δ = 77.16 ppm of CDCl3, the heptuplet at 39.52 ppm of DMSO-d6 for $^{13}C$-NMR. Analytical HPLC was performed using a Dionex Ultimate 3000 pump and Dionex Ultimate 3000 Diode Array Detector (200, 210, 225 and 254 nm) installed with a Phenomenex Gemini-NX 3μ C18 110A, 250 × 4.60 mm column.
Solvent A: H₂O + 0.1% TFA; solvent B: MeCN – H₂O 9 : 1 + 0.1% TFA. For HPLC control, data collection and data handling, Chromeleon software v. 6.80 was used. Preparative HPLC was carried out on an Ultimate 3000 Thermo Scientific system with a Dionex Ultimate 3000 series pump, a Dionex Ultimate 3000 Diode Array Detector (200, 210, 225 and 254 nm), and a Phenomenex Gemini-NX 5μ C18 110 Å, 250 × 21.20 mm column for preparative purifications or a Phenomenex Gemini-NX 5μ C18 110 Å, 250 × 10.00 mm column for semi-preparative purifications. Solvent A: H₂O + 0.1% TFA; solvent B: MeCN–H₂O 9 : 1 + 0.1% TFA. For HPLC control, data collection and data handling, Chromeleon software v. 6.80 was used. UPLC-MS spectra were recorded using an Acquity UPLC H-Class Waters series solvent delivery system equipped with an autoinjector coupled to an Acquity QDa and TUV detectors installed with an Acquity UPLC®BECH C18 1.7 μm column. Solvent A: 5% aq MeCN + 0.1% HCO₂H; solvent B: MeCN + 0.1% HCO₂H. Usually, gradients from A:B 1:0 to 0:1 (5 min) or A:B 1:0 to 0:50 (5 min).

Scheme 1  Attempted bromination of 5 to give bromo-analogs comprised by general structure 4. Reagents and conditions. a) NaH, DMF, –65 to 80 °C; b) Br₂, AcOH or TFA, rt to 90 °C (only the HCl or TFA salt of NF608 was observed) c) Br₂, AcOH, 90 °C (97%).

Scheme 2 Synthesis of key 6-bromo precursor 13 and incorporation of deuterium to give [D₆]-NF608. Reagents and conditions. (a) Trichloroacetyl isocyanate, THF, 0 °C to rt, 2 h, 93%; (b) Br₂, acetic acid, 0–80 °C, overnight, 69%; (c) 2 N NH₃ in methanol, 0 °C to rt, 30 min, 89%; (d) tert-BuOK, DMF, rt, overnight, 95%; (e) NaH, DMF, 0 °C to rt, then lactone 2 in DMF, 0 °C to rt, 18% (f) 2 M aq HCl, 50 °C, 1 h, 94% (g) D₂ (g), Pd/C, NaOH, H₂O, rt, overnight, 57%.

Scheme 3 Tritiation of 13. Reagents and conditions. a) T₂ (515 mbar), Pd/C (30%), NaOH (1 M), H₂O, 3 h, r.t. [23.5 mCi (>99.9% R.C.P.), 23% R.C.Y.]

TIFIC system with a Dionex Ultimate 3000 series pump, a Dionex Ultimate 3000 Diode Array Detector (200, 210, 225 and 254 nm), and a Phenomenex Gemini-NX 5μ C18 110A, 250 × 21.20 mm column for preparative purifications or a Phenomenex Gemini-NX 5μ C18 110A, 250 × 10.00 mm column for semi-preparative purifications. Solvent A: H₂O + 0.1% TFA; solvent B: MeCN–H₂O 9 : 1 + 0.1% TFA. For HPLC control, data collection and data handling, Chromeleon software v. 6.80 was used. UPLC-MS spectra were recorded using an Acquity UPLC H-Class Waters series solvent delivery system equipped with an autoinjector coupled to an Acquity QDa and TUV detectors installed with an Acquity UPLC®BECH C18 1.7 μm column. Solvent A: 5% aq MeCN + 0.1% HCO₂H; solvent B: MeCN + 0.1% HCO₂H. Usually, gradients from A:B 1:0 to 0:1 (5 min) or A:B 1:0 to 0:50 (5 min).
were performed depending on the polarity of the compounds. For data collection and data handling, MassLynx software was used. Compounds were dried under high vacuum or freeze dried using a ScanVac Cool Safe Freeze Drier. The purity of compounds submitted for pharmacological characterization was determined by \(^1\)H-NMR and HPLC to be >95%.

For the tritiation experiments

\(^1\)H-, \(^3\)H- and \(^13\)C NMR spectra were recorded at 300/320 MHz and 75 MHz, respectively, with a Bruker Avance II 300 MHz instrument at 25 °C. The residual solvent signals in the \(^1\)H and \(^13\)C NMR spectra were used as an internal reference (CDCl\(_3\): \(\delta = 7.26\) for \(^1\)H and \(\delta = 77.23\) for \(^13\)C). The mass spectra were obtained by the Bruker Daltonics Esquire 4000 system with a direct input (ESI, stream ACN–H\(_2\)O, a mass range of 50–1200 Da, Esquire Control Software). The HR-mass spectra were obtained in the ESI mode either on a Waters.

Table 1  Binding assay conditions evaluated

<table>
<thead>
<tr>
<th>Buffers (50 mM)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris-HCl</td>
<td></td>
</tr>
<tr>
<td>Tris-HCl + 100 mM NaCl</td>
<td></td>
</tr>
<tr>
<td>Bis-Tris-HCl</td>
<td></td>
</tr>
<tr>
<td>Na(^+)HEPES</td>
<td></td>
</tr>
<tr>
<td>Na(^+)MOPS</td>
<td></td>
</tr>
<tr>
<td>Na(^+)TES</td>
<td></td>
</tr>
<tr>
<td>Na(^+)H(_2)PO(_4)</td>
<td></td>
</tr>
<tr>
<td>Na(^+)PIES</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>pH</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>7.1</td>
<td></td>
</tr>
<tr>
<td>7.4</td>
<td></td>
</tr>
<tr>
<td>7.6</td>
<td></td>
</tr>
<tr>
<td>7.8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Temperature (°C)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Filter washing (mL)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2 × 3</td>
<td></td>
</tr>
<tr>
<td>3 × 3</td>
<td></td>
</tr>
<tr>
<td>2 × 4</td>
<td></td>
</tr>
<tr>
<td>3 × 4</td>
<td></td>
</tr>
<tr>
<td>2 × 5</td>
<td></td>
</tr>
<tr>
<td>3 × 5</td>
<td></td>
</tr>
</tbody>
</table>

Overview of the various assay conditions tested. The pH, temperature and washing conditions were only evaluated using 50 mM Tris-HCl buffer.

![Fig. 3](image1.png)

**Fig. 3** Association and dissociation kinetic experiments of \(^3\)H-NF608 binding to recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Dissociation was initiated after a 2 h equilibration with the radioligand. Shown are pooled, normalized data from 3–4 experiments conducted in triplicate. Nonspecific binding was determined in the presence of 1 mM (S)-glutamate.

![Fig. 4](image2.png)

**Fig. 4** Saturation binding of \(^3\)H-NF608 (16.3 Ci mmol\(^{-1}\)) to recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Shown are pooled, normalized data from 3 experiments conducted in triplicate. Nonspecific binding was determined in the presence of 1 mM (S)-glutamate. From the pooled analysis: \(K_d = 6.61 \pm 0.50\) nM, \(B_{\text{max}} = 4675 \pm 76\) fmol mg\(^{-1}\) protein, \(n_H = 1.07 \pm 0.07\).

![Fig. 5](image3.png)

**Fig. 5** Competition binding at recombinant, homomeric rat GluK1 expressed in sf9 cell membranes. Shown are pooled, normalized data from 3 experiments conducted in triplicate. DA, domoic acid; ATPA, (RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid; KA, kainic acid; QA, quisqualic acid; Glu, (S)-glutamic acid; UBPS10, (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-thiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione.
Micromass Q-TOF Micro mass spectrometer or on a Thermo Fisher Scientific LTQ Orbitrap XLc. The tritiation reaction was performed on a custom-designed tritium manifold system manufactured by RC Tritec AG, Switzerland. Activities were measured on a Perkin-Elmer TriCarb 2900TR liquid scintillation counter (LSC) in a Zinsser Quicksafe A cocktail. The HPLC was performed on a system consisting of a WATERS Delta 600 Pump and Controller, a WATERS 2487 UV detector and a RAMONA radio chromatographic detector from Raytest (Germany) with interchangeable fluid cells. For the preparative runs, the cell with a single small crystal of solid scintillator was used; for analytical runs, the column effluent was mixed with a Zinsser Quickszint Flow 302 cocktail at the ratio of 1:3.

**tert-Butyl (S)-(2-oxooxetan-3-yl)carbamate (2).** To an ice-cooled solution of triphenylphosphine (95%, 7.3 g, 26.53 mmol) in anhydrous THF (50 mL), was added diethyl azidodi-carboxylate (DEAD, 97%, 4.6 mL, 28.95 mmol). The resulting suspension was stirred 50 minutes at room temperature. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The aqueous layer was extracted with EtOAc (3 × 80 mL) and the collected organic layers were washed with brine (80 mL), dried over MgSO4 and filtered. After that, the solvent of the filtrate was removed under reduced pressure to give a residue that was purified by flash chromatography (silica gel, heptane–EtOAc 95:5 to 7:3, gradient) to afford the lactone 2 as a white solid (1.7 g, 37%).1H NMR (600 MHz, CDCl3) δ 5.26 (br s, 1H), 5.20–5.05 (m, 1H), 4.47 (br t, J = 5.1 Hz, 1H), 4.43 (br t, J = 4.7 Hz, 1H), 1.48 (s, 9H). Product described in ref. 12.

(S)-1-((2-‘tert-Butoxycarbonyl)amino-2-carboxyethyl)thieno-[3,2-d]pyrimidin-4-one (3). A solution of thieno[3,2-d]pyrimidin-4(3H)-one (98%, 1 g, 5.88 mmol) in anhydrous DMF (40 mL) was cooled to 0 °C and then sodium hydride (60% w/w in mineral oil, 214 mg, 5.34 mmol) was added. The resulting suspension was stirred 50 minutes at room temperature. After that time, the reaction mixture was cooled again to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (1 g, 5.34 mmol) in anhydrous DMF (20 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 20 mL) to get a white solid that was divided in 6 portions and each one was dissolved in DMSO-MeCN (15:1, 1 mL) and purified by 6 consecutive preparative HPLC purifications (Rt: 19.53 min; flow: 10 mL min⁻¹; A-B 1:0 to 25:75 (25 min); A-B 25:75 (5 min); preferably λ = 254 nm, since DMSO does not absorb) to afford the desired compound 3 as a white solid (206 mg, 11%).

<table>
<thead>
<tr>
<th>Radioligand →</th>
<th>[3H]-SYM2081</th>
<th>[3H]-NF608</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competitor i</td>
<td>$K_i$ [nM]</td>
<td>$n_H$</td>
</tr>
<tr>
<td>(S)-NF608</td>
<td>5.29 ± 0.66</td>
<td>0.99 ± 0.03</td>
</tr>
<tr>
<td>UBP310</td>
<td>22.1 ± 4.6</td>
<td>0.78 ± 0.03</td>
</tr>
<tr>
<td>(RS)-ATPA</td>
<td>2.13 ± 0.21</td>
<td>0.96 ± 0.03</td>
</tr>
<tr>
<td>Kainic acid</td>
<td>76 ± 12</td>
<td>0.99 ± 0.04</td>
</tr>
<tr>
<td>Quisqualic acid</td>
<td>171 ± 93</td>
<td>0.93 ± 0.03</td>
</tr>
<tr>
<td>Domoic acid</td>
<td>1.11 ± 0.20f</td>
<td>0.99 ± 0.04</td>
</tr>
<tr>
<td>(S)-Glutamic acid</td>
<td>140 ± 3e</td>
<td>0.98 ± 0.03</td>
</tr>
</tbody>
</table>

Shown are means ± SEM of at least 3 experiments conducted in triplicate at 12–16 ligand concentrations. a Ref. 7. b Ref. 15. c Ref. 5.
Methyl 3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (9). Methyl 3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (8); methyl 5-bromo-3-(3,2,2,2-trichloroacetyl)ureido)thiophene-2-carboxylate (9) were synthesized according to ref. 13.

Methyl 5-bromo-3-ureidothiophene-2-carboxylate (10). To an ice-cooled solution of 9 (7.84 g, 17.55 mmol) in anhydrous MeOH (70 mL), was added 2 M NH₄ solution (in MeOH, 17.5 mL, 35.09 mmol) and this mixture was stirred at room temperature for 30 minutes, during which time a white solid precipitated. After this period, the white solid was filtered and washed with cold MeOH (3 × 10 mL) to give the compound 10 (4.37 g, 89%) as a white solid with a purity of 98% (determined by ¹H-NMR). ¹H NMR (400 MHz, DMSO-d₆) δ 9.23 (s, 1H), 8.06 (s, 1H), 6.86 (br s, 2H), 3.80 (s, 3H). Product described in ref. 13.

6-Bromothieno[3,2-d]pyrimidine-2(1H,3H)-dione (11). 6-Bromothieno[3,2-d]pyrimidine-2(1H,3H)-dione (11) (581 mg, 2.35 mmol) in anhydrous DMF (11.4 mL) was cooled to 0 °C and then sodium hydride (60% w/w in mineral oil, 85 mg, 2.14 mmol) was added. The resulting suspension was stirred 40 minutes at room temperature. After that time, the reaction mixture was cooled again to 0 °C and a solution of tert-butyl (S)-(2-oxooxetan-3-yl)carbamate (2) (400 mg, 2.14 mmol) in anhydrous DMF (10 mL) was added. The resulting mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched by adding water dropwise until no reaction was observed. The solvent of the reaction mixture was co-evaporated with toluene (3 × 10 mL) to get a white solid that was divided into 7 portions and each one was dissolved in DMSO–MeCN (15:1, 1.5 mL) and purified by 7 consecutive preparative HPLC purifications (Rt: 28.60 min; flow: 10 mL min⁻¹; A (10 min), A-B 75: 25 to 25:75 (25 min), preferably λ = 254 nm because DMSO do not absorbs) to afford the desired compound as a white solid (187 mg, 18%). ¹H NMR (600 MHz, DMSO-d₆) δ 13.06 (br s, 1H), 11.64 (s, 1H), 7.57 (s, 1H), 7.04 (d, J = 8.9 Hz, 1H), 4.44–4.37 (m, 2H), 3.95 (dd, J = 15.2, 11.0 Hz, 1H), 1.21 (s, 9H). ¹³C NMR (151 MHz, DMSO-d₆) δ 170.9, 157.2, 155.1, 150.9, 147.5, 122.4, 122.1, 112.9, 78.2, 51.1, 46.8, 27.8. UPLC-MS (m/z) calcd for C₉H₇BrN₃O₄S [M + Boc]⁺, 233.9; found, 233.9.

(S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]-pyrimidin-1(2H)-yl)-1-carboxyethan-1-aminon chloride (13). A suspension of (S)-2-(6-Bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]-pyrimidin-1(2H)-yl)-2-((tert-butoxycarbonylamino)propanoic acid (12) (122 mg, 0.28 mmol) in 2 M aq HCl (6 mL), was heated to 50 °C during 1 hour. After that time, the solvent and volatiles were removed under reduced pressure to afford the title compound as a white solid (98 mg, 94%), which was used in next reaction step without further purification. ¹H NMR (600 MHz, DMSO-d₆) δ 11.73 (s, 1H), 8.40 (s, 3H), 7.68 (s, 1H), 4.44 (dd, J = 15.0, 6.3 Hz, 1H), 4.27 (dd, J = 15.0, 7.9 Hz, 1H), 4.10 (br t, J = 6.3 Hz, 1H). ¹³C NMR (151 MHz, DMSO-d₆) δ 168.3, 157.2, 151.4, 146.6, 123.0, 121.6, 113.5, 50.5, 44.7. UPLC-MS (m/z) calcd for C₉H₈BrN,O₃S [M + H]⁺, 333.9; found, 333.9.

Sodium [(S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide-6-d ([(D₆]-NF608 disodium salt) and sodium [(S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608 disodium salt). Pd/C (1.8 mg, 10% Pd on activated C, wet) was weighed in a small flask that was repeatedly filled and evacuated with N₂ (3 times), and then D₂ (3 times). In parallel, [(S)-2-(6-bromo-2,4-dioxo-3,4-dihydrothieno[3,2-d]-pyrimidin-1(2H)yl)-1-carboxyethan-1-aminon chloride (13) (9 mg, 0.024 mmol) was weighed in a separate flask that was repeatedly filled and evacuated with N₂ (3 times). Then, water (240 μL) and 1 M aq NaOH (69 μL, 0.069 mmol) were added to afford a suspension that was heated to 60 °C for 5 minutes until getting a clear solution that was transferred to the previous flask with Pd/C. The resulting mixture was repeatedly filled and evacuated with D₂ (3 times), and stirred vigorously at room temperature overnight under D₂ (1 atm). After this period, the reaction mixture was filtered through a plug of Celite®, and the filtrate was washed with water (3 × 3 mL). Then, the filtrate was concentrated in vacuo to give the deuterated hydrogenated disodium salts of products [(D₆]-NF608: NF608 in a 4:1 ratio, as a white solid (4 mg, 57%, 80% D-incorporation).

Sodium [(S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608). ¹H NMR (600 MHz, D₂O) δ 7.29 (br s, 1H), 4.29 (d, J = 7.1 Hz, 2H), 3.75 (t, J = 7.1 Hz, 1H). ¹³C NMR (151 MHz, D₂O) δ 178.6, 163.6, 155.3, 148.5, 136.3, 117.1, 113.3, 54.8, 49.0. UPLC-MS (m/z) calcd for C₉H₈DN,O₃S [M + H]⁺, 257.0; found, 257.0.

Sodium [(S)-1-(2-amino-2-carboxylatoethyl)-2,4-dioxo-1,4-dihydro-2H-thieno[3,2-d]pyrimidin-3-ide (NF608). ¹H NMR (600 MHz, D₂O) δ 8.02 (d, J = 5.5 Hz, 1H), 7.29 (dd, J = 5.5 Hz, 1H), 4.29 (d, J = 7.1 Hz, 2H), 3.75 (t, J = 7.1 Hz, 1H). ¹³C NMR (151 MHz, D₂O) δ 178.6, 163.6, 155.3, 148.5, 136.3, 117.2, 113.3, 54.8, 49.0.

[(³H]-(S)-2-Amino-3-(2,4-dioxo-3,4-dihydrothieno[3,2-d]-pyrimidin-1(2H)yl)propanoic acid [(³H]-NF608). A solution of 13 (1.3 mg, 3.5 μmol) with Pd/C [30%] (2.6 mg, 2 w/w eq.) in H₂O (1 mL) and NaOH (20 μL, 1 M) in round reaction flask (2 mL) equipped with a Teflon-coated stir bar was mounted onto tritium manifold system. The reaction mixture was degassed three times in a repeated freeze–thaw cycle (liquid nitrogen), and pressure of released tritium gas was adjusted to 515 mbar (6.9 Ci). The reaction mixture was vigorously stirred for 3 hours. The reaction mixture was frozen with liquid nitrogen and unreacted tritium gas was reabsorbed in the uranium bad. The reaction mixture was heated up to room temperature and the catalyst was filtered off with a PTFE syringe filter (0.45 μm). The tritiation flask and filter
were rinsed with H2O (3 × 0.6 mL). To remove labile activity, the solvent with addition of EtOH (2 mL) was repeatedly lyophilized (3 × 3 mL H2O/EtOH 50:50). The activity of crude product (63% R.C.P.) was determined at 65 mCi. The crude product was dissolved in H2O (1 mL) and purified by radio-HPLC on a Synergi 4 μm POLAR RP80A 250 × 4.6 mm semi-preparative column using gradient elution with A = water, B = acetonitrile (flow of 4.7 mL min⁻¹, 25 °C, 100% of A for 25 min, 100% of B in 35 min). The retention time of [³H]-NF608 was detected at 19.3 min. Pure [³H]-NF608 was isolated in total activity 23.5 mCi (16.3 Ci mmol⁻¹), 23% R.C.Y. The specific activity was determined by HRMS at 16.3 Ci mmol⁻¹. ³H-NMR (320 MHz, D2O): δ 8.08 (1 T, s). HRMS (ESI): calc. for C₉H₇N₂O₈S [M – 1] 256.0318; found 256.0319.

Pharmacology

Recombinant homomeric rat GluK1(Q)₁₄, GluK2(V,C,R)₅ and GluK3₅ were expressed in sf9 insect cells as previously described.⁵ Rat whole brain (mixed sex) crude synaptosomal (P2) membranes were prepared by standard methods.¹⁴ For use in binding assays, an aliquot of membranes was thawed and washed four times by centrifugation 48 000 × g, 15 min at 4 °C with Ultra-Turrax resuspension in 25 mL ice-cold hypotonic buffer (5 mM Tris-HCl, pH 7.4, 4 °C). Membranes were then resuspended in assay buffer (50 mM Tris-HCl, pH 7.1, 4 °C). Binding assays were conducted in a volume of 250 μL at 4 °C and kinetic and saturation assays terminated by rapid filtration through 0.3% (w/v) polyethylenimine-treated GF/C-type glass fiber filters (VWR filter #696; VWR, Denmark) on 12-well Millipore filtration manifolds (Millipore, Darmstadt, Germany), washing twice with 4 mL ice-cold assay buffer. Filters were equilibrated in 3 mL EcoScint scintillation fluid (National Diagnostics, Atlanta, GA) for 12 h and radioactivity detected as DPM using a TriCarb 2900 scintillation counter (PerkinElmer, Waltham, MA). Non-specific binding was determined in the presence of 1 mM (S)-glutamate. In competition experiments, bound and free radioligand were separated by cold filtration through GF/B glass fiber filters in UniFilter-96 microtitre plates (PerkinElmer) on a FilterMate manifold (PerkinElmer) using two washes with ice-cold assay buffer. Filters were dried 1 hour at 70 °C and 50 μL Microscint 20 (PerkinElmer) was added. Radioactivity was detected as DPM using a TopCounter (PerkinElmer).

Binding data were analyzed with GraphPad Prism v6 (GraphPad Software, San Diego, CA) using: one-site Kᵢ and four-parameter logistic equations for competition data, one-site-homologous equation for [³H]kainate Kᵢₜ determination, mono-exponential rate equations for association and dissociation data and one-site total and nonspecific binding for [³H]-NF608 saturation binding.

Abbreviations

KA Kainic acid
Glu (S)-Glutamic acid
DA Domoic acid
QA Quisqualic acid
NF608 (S)-2-Amino-3-{2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl}propanoic acid
ATPA (RS)-2-Amino-3-{3-hydroxy-5-tert-butyloxazol-4-yl}propanoic acid
UBP310 (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxythiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione

Acknowledgements

The authors thank the Department of Drug Design and Pharmacology and the Academy of Sciences of the Czech Republic (program RVO: 61388963) for the financial support.

References


